Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 12-Month Low - Here's What Happened

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report)'s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $30.46 and last traded at $31.97, with a volume of 206071 shares changing hands. The stock had previously closed at $32.43.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on RARE shares. JPMorgan Chase & Co. upped their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Wedbush restated a "neutral" rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Piper Sandler dropped their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, December 20th. Finally, Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus price target of $92.79.

Remove Ads

Ultragenyx Pharmaceutical Trading Up 3.0 %

The company has a market cap of $3.21 billion, a P/E ratio of -5.38 and a beta of 0.61. The company's fifty day moving average is $39.38 and its 200 day moving average is $44.88.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at $2,358,014.08. This represents a 5.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Emil D. Kakkis sold 25,000 shares of the business's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the completion of the transaction, the chief executive officer now owns 2,158,985 shares in the company, valued at $91,713,682.80. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,643 shares of company stock valued at $5,256,268 in the last ninety days. Company insiders own 5.80% of the company's stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 740.0% in the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock worth $4,802,000 after purchasing an additional 76,150 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares in the last quarter. Y Intercept Hong Kong Ltd lifted its holdings in Ultragenyx Pharmaceutical by 193.1% in the third quarter. Y Intercept Hong Kong Ltd now owns 19,151 shares of the biopharmaceutical company's stock worth $1,064,000 after buying an additional 12,617 shares during the period. Geode Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock valued at $87,296,000 after acquiring an additional 65,623 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Ultragenyx Pharmaceutical by 2,275.8% in the 4th quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock worth $2,567,000 after acquiring an additional 58,442 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.